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ABSTRACT
The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have 
supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing 
patient access to biologics. Following technological advances, other innovative biologics, such as “bio-
betters” or “value-added medicines,” are now reaching the market. These innovative biologics differ from 
the reference product by offering additional clinical or non-clinical benefits. We discuss these innovative 
biologics with reference to CT-P13, initially available as an intravenous (IV) biosimilar of reference 
infliximab. A subcutaneous (SC) formulation, CT-P13 SC, has now been developed. Relative to CT-P13 IV, 
CT-P13 SC offers clinical benefits in terms of pharmacokinetics, with comparable efficacy, safety, and 
immunogenicity, as well as increased convenience for patients and reduced demands on healthcare 
system resources. As was once the case for biosimilars, nomenclature and regulatory pathways for 
innovative biologics require clarification to support their uptake and ultimately benefit patients.
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Advancing technologies have enabled further innovations in biolo-
gic development, resulting in medicines that offer benefits beyond 
those offered by reference biologics, or their biosimilars. However, 
a lack of consensus on nomenclature and regulatory approaches 
toward these innovative biologics threatens their successful uptake, 
now that increasing numbers of these medicines are reaching the 
market. In addition, requirements for clinical and pharmacoeco-
nomic evaluation must also be carefully considered and met by 
developers, to ensure physician and patient confidence in these 
innovative medicines. We examine some of these issues, by drawing 
on experiences with biosimilars and focusing on innovative biolo-
gics such biobetters and value-added medicines (VAMs), with 
particular reference to the subcutaneous (SC) formulation of the 
infliximab biosimilar CT-P13 (CT-P13 SC).
Many biologics are available for the treatment of patients with 
immune-mediated inflammatory diseases (IMIDs), with SC treat-
ment options being developed in addition to intravenous (IV) 
medications (Supplementary Figure 1). For the first tumor necro-
sis factor (TNF) inhibitor, infliximab, initial approval was gained 
in 1998 from the United States (US) Food and Drug 
Administration (FDA), for the treatment of Crohn’s disease 
(CD).1 Infliximab indications approved by the FDA and 
European Medicines Agency (EMA) now encompass rheumatoid 
arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis 
(PsA), psoriasis, CD, and ulcerative colitis (UC) in adults, as well 
as CD and UC in pediatric patients.2,3
Several biosimilars of TNF inhibitors are now available 
(Supplementary Table 1). CT-P13 was the first infliximab biosi-
milar to receive regulatory approval for all indications of the 
reference product (RP).4–6 This followed the demonstration of 
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equivalence to infliximab RP in terms of efficacy in the Phase III 
PLANETRA study,7 and in terms of pharmacokinetics (PK) in the 
Phase I PLANETAS study.8 Randomized controlled trials of CT- 
P13 in over 1,200 patients have provided evidence of biosimilarity 
and switchability consistently, while a risk management plan 
encompassing more than 5,000 patients has been implemented 
to monitor the efficacy and safety of CT-P13 data globally 
(Supplementary Table 2). The advent of biosimilars has facilitated 
substantial cost savings for health-care systems, with market com-
petition stimulated by the reduced costs of biosimilars relative to 
RPs, enabling greater patient access to biologic therapy,9 although 
uptake has varied globally.
While biosimilars are biologics that have no clinically mean-
ingful differences from their RP,10 advances in biologic devel-
opment have led to innovative medicines that offer 
improvements for patients versus the RP. “VAMs” and “bio-
betters” (or “biosuperiors”) are terms that have been used to 
describe such products, although these terms are not consis-
tently defined or used, and definitions may overlap. The first 
biobetter to receive FDA approval, in 1996, was a fast-acting 
insulin analogue, insulin lispro, produced by altering the 
amino acid sequence at two positions.11,12 Subsequently, multi-
ple strategies, often involving molecular engineering, have 
been used in biobetter development, while varied approaches, 
including drug repositioning and reformulation, have been 
taken to develop VAMs. Innovation has recently been achieved 
for infliximab with the development of CT-P13 SC (Table 
113–23), with changes in both the formulation and administra-
tion route relative to the IV-administered CT-P13 (CT-P13 
IV). CT-P13 SC has been approved by the EMA for the treat-
ment of RA, AS, CD, UC, PsA, and psoriasis, and is the first 
SC-administered infliximab to receive regulatory approval in 
any territory.4,24,25
Defining innovative biologics
Biosimilars are biologic medicines that have an identical pri-
mary molecular structure and comparable quality characteris-
tics and non-clinical profile to their RP, a biologic licensed by 
the relevant authority.10,26 Biosimilars have no clinically mean-
ingful differences in safety, purity, and potency from the RP, 
although minor differences are likely due to the complexity of 
biologics and differences in manufacturing processes.10,26 
Regulatory pathways for biosimilars are now well established, 
with 59 biosimilars currently authorized via the EMA centra-
lized procedure (as of November 24, 2020)27 and 28 biosimilars 
licensed by the US FDA (as of July 7, 2020).28
Due to technology advances, the development of improved 
versions of approved biologics, rather than biosimilars, has 
become possible. A biobetter is a recombinant protein drug 
that is in the same class as an existing biopharmaceutical and 
targets the same epitope but has been modified to gain specific 
attributes. Relevant modifications may include: a new drug 
delivery method or modifications to provide clinically relevant 
improvement(s) versus the existing biological product (such as 
improved efficacy, safety or tolerability, or reduced 
immunogenicity).29,30 For example, the type II, glycoengi-
neered anti-CD20 monoclonal antibody obinutuzumab is 
a rituximab biobetter, with a different mechanism of action 
compared with its type I RP.31–33 Biobetters can also be easier 
to administer, or may have an improved dosing regimen (e.g., 
due to a longer serum half-life).34,35
VAMs have been defined by Medicines for Europe as “med-
icines based on known molecules that address healthcare needs 
and deliver relevant improvement for patients, healthcare pro-
fessionals (HCPs) and/or payers.”36 Relevant improvements 
might be related to the efficacy or safety profile, administration 
method or ease of use, or could result from new indications or 
patient populations being targeted.36 Strategies of reposition-
ing, reformulation, or combination (with other drugs, devices, 
or services), collectively referred to as drug repurposing, may 
enable a medicine to deliver added value.36 However, defini-
tions and/or classifications of repositioning and reformulation 
vary, and not all changes will provide added value.37 
Repositioning may involve identifying a new indication for 
a drug that is anatomically and/or therapeutically distinct 
from the original indication, or a different pharmacological 
target in a similar indication.37 However, “repositioning” has 
also been used to describe new uses in similar indications, or 
drugs newly launched in major (rather than emerging) phar-
maceutical markets.37 Reformulation might include changes to 
the release profile, pharmaceutical form, or route of 
Table 1. Overview of clinical trials of subcutaneous CT-P13.
Study
Phase I CT-P13 SC 
1.5 study
Phase I CT-P13 
SC 1.6 study
Phase I/III CT-P13 
SC 3.5 study











Population Healthy subjects CD UC, CD RA Healthy subjects
Primary endpoint Safety Dose-finding 
(up to W30)
PK (W22) Dose-finding (up to W30) Efficacy (W22) PK (up to W12)
Test, reference CT-P13 SC (PFS), 
CT-P13 IV
CT-P13 SC (PFS), 
CT-P13 IV
CT-P13 SC (PFS), 
CT-P13 IV
CT-P13 SC (PFS), 
CT-P13 IV
CT-P13 SC (PFS), 
CT-P13 IV





















UEGW 201713 DDW 2018 (Part 1 
W30);14 ECCO 2019 
(Part 1 W54)15
UEGW 2019 (Part 2 
W30);16 ECCO 2020 
(Part 2 W54)17
EULAR 2018 (Part 1 
W30);18 EULAR 2019 
(Part 1 W54)19
EULAR 2019 (Part 2 
W30);20 ACR 2019 
(Part 2 W54);21 
Westhovens et al.22
ECCO 201923
ACR, American College of Rheumatology; AI, autoinjector; CD, Crohn’s disease; DDW, Digestive Disease Week®; ECCO, European Crohn’s and Colitis Organisation; EULAR, 
European League Against Rheumatism; IV, intravenous; NI, non-inferiority; PFS, prefilled syringe; PK, pharmacokinetics; RA, rheumatoid arthritis; SC, subcutaneous; UC, 
ulcerative colitis; UEGW, United European Gastroenterology Week; W, Week.
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administration of a drug, or changes to excipients with no 
impact on PK parameters.37 This definition excludes changes 
to the chemical structure of the drug itself, or development of 
a new product without altering the formulation (such as 
a change in dose), although these scenarios have also been 
described as “reformulation.”37 Drug repurposing generally 
involves off-patent molecules38,39 but can occur for discontin-
ued drugs or molecules that have never been commercialized.37 
VAMs are beginning to emerge in the biologic arena as med-
icines come off patent.39
Regulatory approaches to innovative biologics
The biosimilar regulatory landscape
Biosimilar regulatory pathways are now well established, sup-
ported by guidance documents issued by regulatory authorities 
such as the EMA (Supplementary Figure 2). Biosimilar develop-
ment programs aim to establish “biosimilarity” based on 
a stepwise “totality of evidence” approach (Supplementary 
Figure 3).10,26 Extensive, varied testing methods are used to 
demonstrate that physicochemical and biological attributes of 
the candidate biosimilar and RP are proven identical or 
comparable.10,40 For example, non-clinical data supporting 
FDA approval of CT-P13 demonstrated that the biosimilar was 
highly similar to its RP.41 In addition, non-clinical studies of CT- 
P13 demonstrated similarity in human tissue binding, off-target 
toxicity, and PK/toxicokinetic profiles to the European Union 
(EU)-sourced RP.42 Clinical trials must then establish similarity 
of the candidate biosimilar to the RP in terms of PK and efficacy; 
pharmacodynamic, immunogenicity, and safety profiles must 
also be comparable.10,43 FDA approval of CT-P13 followed the 
demonstration that CT-P13 and the EU-sourced RP were highly 
similar in terms of PK, immunogenicity, safety, and efficacy 
across studies in patients with RA and AS,7,8 as well as the three- 
way comparability of PK and safety between CT-P13, EU- 
sourced reference infliximab, and US-sourced reference 
infliximab.44 The requirements of biosimilar clinical studies con-
trast with those for new drug development, for which the main 
goal is to demonstrate clinical efficacy in each indication 
(Supplementary Figure 3). As such, data requirements for the 
approval of biosimilars and new biologics differ (Supplementary 
Figure 4). Following regulatory approval, a risk management 
plan and pharmacovigilance system (for the EMA) or a risk 
evaluation and mitigation strategy (for the FDA) may need to 
be established.40,45 Real-world data have been accumulating for 
biosimilars,46–50 supporting increased confidence in these inno-
vative medicines and their ongoing clinical use.
During clinical development of biosimilar monoclonal anti-
bodies, the potential impacts of anti-drug antibodies (ADAs) 
on PK, efficacy, and safety51,52 mean that immunogenicity 
assessment is crucial.10,53 However, the performance of immu-
nogenicity assays poses a challenge for inter-study 
comparability,54,55 with reported proportions of infliximab 
ADA-positive patients varying widely (0–65.3%).56 FDA gui-
dance notes that biosimilar efficacy studies may not be required 
if the results of PK/pharmacodynamic and clinical immuno-
genicity studies provide adequate evidence for biosimilarity.10
Local biosimilar regulatory guidance applies for each jurisdic-
tion globally, although there may be similarities between regula-
tors due to shared scientific perspectives and collaboration.57 
Regulatory approaches can vary, such as regarding requirements 
for submission of in vivo data,58 or the use of local versions of the 
RP for biosimilarity assessment.57 For example, the EMA allows 
RPs for clinical trials to be produced outside EU, while the FDA 
requires that at least one clinical PK study is conducted using the 
US-licensed version of the RP.10,26 Studies evaluating a biosimilar 
in patients of a particular ethnicity are also required by some 
regulatory agencies, such as in Japan:59 to support approval of CT- 
P13, bridging and extension studies were required in Japanese 
patients (Supplementary Table 2). Robust biosimilar development 
plans should include strategies to ensure alignment with the 
approaches of different regulatory agencies to minimize any inef-
ficiencies or delays, including taking advantage of opportunities 
for discussion with the agencies.60–62 However, proposals to 
further optimize regulatory pathways have been made, involving 
greater alignment between agencies and re-evaluation of biosimi-
lar regulatory approval requirements.63 One suggestion is that 
perhaps Phase III comparative efficacy studies should no longer 
be required: the decisive factor in biosimilar regulatory decisions, 
to date, appears to have been high similarity in terms of analytical 
characterization and human PK studies, rather than the outcome 
of efficacy trials.63 In addition, large pre-approval clinical studies 
may not be needed in the future as advancing analytical technol-
ogies allow more discriminatory evidence to be collected alongside 
comparative PK and postmarketing monitoring.64
Design of biosimilar efficacy studies: establishing 
equivalence margins
Biosimilar efficacy trials must be carefully designed. Studies 
should be conducted in populations that allow the greatest 
sensitivity for the detection of potential differences between 
the candidate biosimilar and its RP.10,43 Equivalence, rather 
than non-inferiority, study designs allow demonstration that 
the candidate biosimilar is neither inferior nor superior to its 
RP.10,43 Prespecified equivalence margins must be determined, 
reflecting acceptable variations in efficacy with reference to 
existing data for the RP: this is used to determine target study 
population size.65,66 Typically, equivalence margins are sym-
metrical and two-sided; the 95% confidence interval (CI) for 
the difference in the relevant endpoint between biosimilar and 
RP should be fully contained within the equivalence margin to 
support the conclusion of equivalence.
There is currently no standard method to define the prespeci-
fied equivalence margin. To support CT-P13 approval, EMA 
guidelines were consulted67,68 and a systematic literature review 
(unpublished) was conducted to inform determination of the 
equivalence margin for the pivotal PLANETRA study of CT-P13 
in patients with RA.7 Treatment differences in 20% improvement 
in American College of Rheumatology criteria (ACR20) response 
rates for patients with RA (receiving concomitant methotrexate) 
treated with reference infliximab versus placebo ranged from 
17.6% to 37.8% (Supplementary Table 3). Among other considera-
tions, these response rates informed the 15% equivalence margin 
used in the PLANETRA study.7 Subsequently, equivalence of 
efficacy for CT-P13 and reference infliximab was concluded: the 
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95% CI for the difference in ACR20 response rates at Week 30 was 
−6% to 10%, contained within the prespecified −15% to 15% 
equivalence margin.7
The regulatory landscape for VAMs and biobetters
No standardized guidance is available from major regulatory 
agencies regarding the approval pathways for innovative biologic 
drugs. Varied regulatory pathways have been taken to gain 
approval for repurposed drugs.69 For example, obinutuzumab 
received a positive opinion from the EMA through the centralized 
procedure with an orphan medicinal product designation for 
untreated chronic lymphocytic leukemia (CLL),32 while FDA 
approval was received via a Biologics License Application (BLA) 
with Breakthrough Therapy designation.70 In addition, the SC 
formulation of rituximab received EU marketing authorization 
following extension applications for the new route of 
administration,71 while FDA approval was via BLA.72
The EMA hybrid medicines pathway evaluates applications for 
“a generic medicine that is based on a reference medicine but has 
a different strength, a different route of administration or a slightly 
different indication from the reference medicine” that rely on data 
for both the reference and new products.73 In the US, applications 
under the 505(b)(2) pathway sometimes concern changes to 
approved drugs (for example, changes to dosage, strength, route 
of administration, or formulation) where the applicant relies on 
information from published literature or previous FDA findings.74 
Until March 23, 2020, the 505(b)(2) pathway was also open to 
follow-on versions of biologics approved viaa New Drug 
Application – the regulatory process for biologic approval before 
the Biologics Price Competition and Innovation Act was 
adopted.75–77 After this date, biologics differing from approved 
products are unlikely to be considered under the biosimilar 
approval pathway by the FDA and will likely require a full 
BLA.75 While several recombinant protein therapeutics have 
been approved under the 505(b)(2) pathway in the past, some 
have been licensed as biosimilars in the EU,77 which could suggest 
that they do not offer clinically meaningful benefits for patients 
compared with their respective RPs.
Future regulatory pathways might vary, depending on the 
regulatory agency’s perspective on the biobetter and VAM con-
cepts, and might depend on the nature of differentiation from the 
RP (e.g., clinical outcomes vs. patient convenience). Importantly, 
the clinically relevant differences between biobetters and RPs 
mean that indication extrapolation, as permitted for 
biosimilars,10,43 does not apply.30 However, we suggest that indi-
cation extrapolation might be appropriate for VAMs, depending 
on the nature of the benefit they provide. Regardless of the avail-
ability of regulatory guidance documents, discussions with leading 
regulatory agencies and strategic alignment with the requirements 
of each agency can facilitate appropriate development decisions 
and help to avoid delays.
Despite uncertainty and the lack of dedicated, expedited 
regulatory pathways, opportunities may remain for developers 
to streamline development of biobetters and VAMs, particu-
larly as placebo-controlled trials are not warranted. Existing 
knowledge of the drug target can reduce research and devel-
opment costs, while prior development of related drugs can 
assist biomarker selection, boosting efficiency.78–80 In addition, 
safety monitoring is likely to focus on adverse events already 
known to be related to the established target pathway.78 
However, it is essential that sufficient, novel, head-to-head 
clinical data are available to support comparison between the 
innovative biologic and RP for determination of added value.
Innovative biologic development: CT-P13 SC case 
study
Non-clinical and clinical development of CT-P13 SC
Both the formulation and administration route of CT-P13 SC 
are altered relative to CT-P13 IV. The EMA Summary of 
Product Characteristics indicates that several excipients differ 
between CT-P13 IV and CT-P13 SC, and states that CT-P13 SC 
was well tolerated in rabbits at the actual concentration to be 
used in humans in preclinical safety evaluations.4 Reflecting 
the need for extensive non-clinical characterization of innova-
tive biologics, more than 20 physicochemical and 40 functional 
and biological tests (unpublished) were employed during the 
development of CT-P13 SC.41
The clinical development program for CT-P13 SC (Table 1) 
used CT-P13 IV as the RP. The CT-P13 SC 1.5 dose escalation 
study was conducted in healthy volunteers to establish the 
safety of CT-P13 SC; cohorts received one of the three doses, 
beginning with the lowest dose, with subsequent cohorts 
initiated based on the absence of dose-limiting toxicities.13 
Across all CT-P13 SC and CT-P13 IV cohorts, bioavailability 
was 60.56% (95% CI: 51.93–70.63).81 The dose-linearity in PK 
profiles following a single CT-P13 SC injection13 paved the way 
for clinical studies in patient populations. The Phase I CT-P13 
SC 1.6 study was conducted in patients with inflammatory 
bowel disease (IBD): Part 1 was a dose-finding study, con-
ducted in patients with CD,15 and Part 2 evaluated non- 
inferiority in terms of PK in patients with CD or UC.16 The 
Phase I/III CT-P13 SC 3.5 study, conducted in patients with 
RA, comprised two Parts: Part 1 was dose-finding study,19 
while Part 2 established non-inferiority of CT-P13 SC versus 
CT-P13 IV in terms of efficacy and evaluated a single switch 
from CT-P13 IV to CT-P13 SC (Supplementary Figure 5 shows 
the study design).22 While the aforementioned studies admi-
nistered CT-P13 SC via prefilled syringe, administration of CT- 
P13 SC via autoinjector was assessed as an alternative in the 
Phase I CT-P13 SC 1.9 study in healthy volunteers.23
In Part 1 of the CT-P13 SC 3.5 study, efficacy profiles were 
similar for CT-P13 SC and CT-P13 IV arms up to Week 54.19 
In Part 2, non-inferiority between treatments was concluded 
for the primary efficacy endpoint, change from baseline to 
Week 22 in Disease Activity Score in 28 joints (DAS28)- 
(C-reactive protein [CRP]), since the lower limit of the 95% 
CI for the estimate of treatment difference (0.27 [95% CI: 
0.02–0.52]) exceeded the prespecified non-inferiority margin 
of −0.6.22 In addition, ACR response rates were similar 
between treatment arms up to Week 22.22 Efficacy up to 
Week 54 was similar between treatment arms in terms of 
mean DAS28 (CRP) scores, even after the CT-P13 IV group 
switched to CT-P13 SC at Week 30.22 In terms of PK, mean 
serum concentrations consistently exceeded the threshold tar-
get–therapeutic concentration in Part 119 and Part 2.22 Drug 
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exposure was well maintained, with trough serum concentra-
tions higher and more constant with CT-P13 SC versus CT- 
P13 IV:19,22 this high consistency in drug exposure could 
enhance treatment options for patients.19 In addition, overall 
safety profiles were comparable between arms for both study 
parts.19,22 In Part 2, the majority of localized injection site 
reactions, infusion-related reactions (recorded for CT-P13 IV 
only), and systemic injection reactions were grade 1–2 in 
intensity.22
Detecting immunogenicity provides valuable information 
about treatment efficacy, since development of ADAs can contri-
bute to suboptimal drug concentrations and lack or loss of 
response,50,56,82 although the impact of low levels of ADAs on 
drug retention needs to be confirmed.83 It is also important to 
consider that different types of ADAs can have different clinical 
consequences: while neutralizing ADAs prevent target binding, 
non-neutralizing ADAs forming immune complexes may also 
lead to changes in clearance, as well as immune complex– 
mediated hypersensitivity reactions.84 A range of methods can be 
used to detect ADAs, with varying sensitivities and free drug 
tolerances, including electrochemiluminescent (ECL) immunoas-
say, enzyme-linked immunosorbent assay (ELISA), radioimmu-
noassay, and homogeneous mobility shift assay.85 Clinical studies 
for CT-P13 used a high-sensitivity ECL-based affinity capture 
elution assay to detect ADAs, offering improved sensitivity and 
drug tolerance compared with the ELISA method used in clinical 
studies for the RP.85
Immunogenicity rates for IV- and SC-administered biologics 
vary on a case-by-case basis: the immunogenicity rate for the IV 
route was higher than that for the SC route for abatacept,86,87 while 
contradictory findings were observed for golimumab,88–90 
rituximab,91–94 tocilizumab,95,96 trastuzumab,97,98 and 
vedolizumab.99–101 The potential for increased immunogenicity 
with SC- versus IV-administered biologics has been suggested, due 
to factors including proximity to antigen-presenting Langerhans 
cells,102,103 with particular concerns for infliximab ascribed to its 
chimeric nature.104 For the recently approved SC infliximab, its 
immunogenicity appeared lower compared with its IV formula-
tion at Week 22 in RA patients (CT-P13 SC: 50.3%; CT-P13 IV: 
61.5%).22 However, features other than administration route and 
biologic structure influence immunogenicity, including formula-
tion, protein concentration, dose and administration device, 
patient population, genotype (as recently demonstrated for 
infliximab105,106), immunosuppressive effects of the drug, and 
concomitant medications.102,107 Administration intervals, which 
impact drug serum concentrations, can also influence 
immunogenicity.107 As well as differences between IV and SC 
administration, a Phase I study comparing SC and intramuscular 
(IM) administration of an experimental infliximab formulation 
identified lower immunogenicity and greater efficacy with SC 
versus IM administration108 – a finding considered in the devel-
opment of CT-P13 SC.
The proportion of ADA-positive patients was similar 
between the CT-P13 SC and CT-P13 IV arms in Part 2 of the 
CT-P13 SC 3.5 study (51.9% and 62.1%, respectively, at Week 
30, prior to patients in the CT-P13 IV arm switching to CT-P13 
SC).22 As discussed, factors including the change in formula-
tion and administration intervals might contribute to any such 
differences in immunogenicity. Alternatively, the higher pre- 
dose drug concentrations maintained with CT-P13 SC versus 
CT-P13 IV19,22 could lead to differences in immunogenicity. 
Antibody responses are impacted by the antigen dose, with 
both very low and high doses able to induce immune tolerance 
(Supplementary Figure 6). In high-zone tolerance, high con-
centrations of a soluble protein induce long-lasting, specific 
immune tolerance,109,110 while lower concentrations stimulate 
antibody responses, exemplified by the association between 
low serum infliximab levels early in treatment and subsequent 
detection of ADAs.50,111,112 In the case of CT-P13, one hypoth-
esis is that the higher trough concentrations achieved following 
SC administration (Figure 1113) remain within the high-zone 
tolerance range, and thereby offset the potentially more immu-
nogenic nature of the SC route. Another possibility is that high 
concentrations of unbound CT-P13, achieved through fre-
quent SC administration, might restrict the development of 
ADAs otherwise elicited by target–therapeutic antibody 
immune complexes.109
Regulatory approval of CT-P13 SC and future plans
CT-P13 SC recently received regulatory approval in the EU, initi-
ally for the treatment of patients with RA, sought through an 
expanded authorization for the new formulation as a line 
extension.24,114 Subsequently, regulatory approval for CT-P13 SC 
has been extended to the adult indications approved for CT-P13 
IV, encompassing IBD, AS, PsA, and psoriasis,4 following market-
ing authorization granted by the European Commission in 
July 2020.25 For regulatory approval of CT-P13 SC via an exten-
sion application,115 additional dose-finding, dose-limiting toxicity, 
and device studies were conducted (Table 1), following on from 
the assessments supporting biosimilar approval of CT-P13 IV. 
When FDA approval is sought for CT-P13 SC, it is likely that 
new drug evaluation pathways will be followed.24 In line with the 
conclusions of a review of regulatory perspectives toward 
biobetters,30 discussions with the FDA indicated that a pivotal 
study in each requested indication would be required for CT- 
P13 SC approval, rather than the biosimilar regulatory pathway 
being followed.24
Pharmacoeconomic considerations for innovative 
biologics
Adoption of biosimilars in place of RPs has enabled healthcare 
systems to achieve substantial cost savings, with biosimilar 
price discounts relative to RPs stimulating market 
competition.9 Prior to the introduction of CT-P13, budget 
impact analyses suggested that its uptake in six European 
countries could deliver net savings of €15.3 million or 
€20.8 million (depending on whether switching from the RP 
was permitted) over 3 years; these savings could be reinvested 
to finance the treatment of an additional 1,200–1,800 
patients.116 In practice, the United Kingdom has saved 
£99,400,000 by switching to infliximab biosimilars for the 
treatment of patients with RA and IBD during the 2017/18 
financial year (Supplementary Table 4). In addition, decreases 
in average European list prices have improved patient access to 
biologics.9 For example, following the introduction of inflix-
imab biosimilars in Norway in 2013, the costs of infliximab 
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therapy decreased by almost half, while the number of patients 
receiving infliximab biosimilars increased substantially 
(Supplementary Figure 7). However, the biosimilar landscape 
varies between countries, linked to differences in biosimilar 
policies and reimbursement systems.117 Differences in biosimi-
lar discount rate relative to RPs may also influence biosimilar 
uptake: for example, analysis of IMS data to the second quarter 
of 2017 showed that discount rates exceeding 50% for CT-P13 
versus the infliximab RP were linked with CT-P13 market 
shares approaching 100% (across all indications) in Bulgaria 
(from 2014) and Norway (from 2015), contrasting with dis-
count rates and market shares both below 50% in Spain and 
France.
Beyond the benefits of cost savings from biosimilar uptake 
enabling additional patients to be treated, improved cost- 
effectiveness may allow biologic treatment to be extended to 
other patient groups or earlier in the course of disease.117 This 
implies that cost-effectiveness analyses conducted for RPs 
should be revisited following biosimilar availability.117 
Analyses should use net prices to accurately assess value;118 
however, limited access to pricing information, as well as 
variations between countries and treatment settings, can lead 
to biased cost-effectiveness estimates. In addition, national 
variations challenge extrapolation of analyses between 
countries;117 methodologies should be appropriate for the set-
ting, considering the resources of the healthcare system.119 
Cost savings from biosimilar uptake could also support patient 
access to other treatments or be reinvested in healthcare sys-
tems (such as through employing additional HCPs).49,117 
Furthermore, competition between biosimilars and RPs may 
encourage further innovation by developers,117 leading to the 
development of biobetters or VAMs.
VAMs and biobetters may provide several benefits for 
healthcare systems (Supplementary Table 5). Irrational use of 
medicines – including poor adherence, off-label use, prescrib-
ing inefficiency, and medicine wastage – places a significant 
cost burden on healthcare systems.120,121 Medicines offering 
increased convenience for patients might improve adherence, 
while drug repositioning/reformulation and packaging optimi-
zation could limit off-label use and medicine wastage, 
respectively.120 Ready-to-use formulations could also reduce 
the medicine handling burden for HCPs.120 Alongside benefits 
for patients, changes in drug administration route, such as 
from IV to SC, might generate cost savings for healthcare 
systems as in-hospital treatment time and resources are 
reduced.122–125 The increased availability of treatment options 
offering benefits over RPs could impact price setting for other 
innovative medicines being launched for that indication, redu-
cing their budget impact.120 Furthermore, while therapeutic 
advantages mean that biobetters may attract a price premium, 
this might be offset by other factors such as reduced dosing 
frequency.30
Potential budget savings could be used to provide persona-
lized patient care, which may lead to further cost savings. 
Therapeutic drug monitoring, encompassing measurement of 
ADAs and drug PK parameters, could be used to optimize 
therapy for individual patients with IMIDs.126,127 Dashboards 
guiding personalized dosing could help this approach to deli-
ver clinical benefits,128 as recently demonstrated in patients 
with IBD.129 Biomarker monitoring, such as for fecal calpro-
tectin in patients with IBD, can also provide useful insights into 
disease and therapeutic status.130 The objective information 
gained from these techniques could be used to inform treat-
ment decisions, ultimately improving patient care.
Delivering the benefits of innovative biologics to 
patients
Potential benefits of VAMs and biobetters for patients
Innovative approaches to medicine development can deliver 
a multitude of benefits for patients, by addressing unmet needs 
and offering alternatives to existing treatments. For example, the 




























Maintenance steady state time point (Week)
Induction + 5 mg/kg IV Q8W
Induction + 120 mg SC Q2W
AUC
AUC
Figure 1. Generalized simulated serum concentration–time profile for CT-P13 following administration via IV or SC routes. Adapted with permission from Schreiber 
et al.113 AUC, area under the concentration–time curve; Cmax, maximum serum concentration; Ctrough, trough serum concentration; IV, intravenous; Q2W, every 2 weeks; 
Q8W, every 8 weeks; SC, subcutaneous.
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compared with rituximab in the treatment of CLL,131,132 with 
efficacy also identified in rituximab-refractory patients.133 The 
development of innovative medicines may also encourage inves-
tigation of their use in novel indications in which existing products 
are not approved. In addition, combination products could offer 
improved convenience and ease of medicine delivery,38 while 
further benefits may be achieved by replacing RPs with biobetters 
or VAMs in existing combination therapies.
Reformulated medicines could allow dosing to be tailored to 
individual patients, alongside optimizing PK and improve-
ments in efficacy, safety, and patient convenience and 
experience.38,120 For CT-P13 SC, immunogenicity and PK 
have previously been discussed. In addition, the altered admin-
istration route for CT-P13 SC could offer patients increased 
flexibility and convenience: two factors contributing to patient 
preferences for SC- versus IV-administered anti-TNFs, along-
side reduced hospital attendance and increased ease of use 
(Supplementary Table 5). The choice of autoinjector and pre-
filled syringe administration devices for CT-P13 SC could also 
increase treatment options for patients. In patients with UC 
receiving golimumab and patients with RA receiving metho-
trexate, patient satisfaction was high with autoinjector admin-
istration and ease of use was greater with autoinjector versus 
prefilled syringe administration,134,135 indicating the attractive-
ness of this approach. SC administration also offers the benefit 
of being less invasive than IV administration, although pain- 
free administration of larger fluid volumes and minimizing 
injection site reactions represent challenges of the SC route 
(Supplementary Table 5).
In the future, availability of both CT-P13 IV and CT-P13 SC 
could facilitate personalization of therapy. To date, CT-P13 SC 
maintenance treatment has been evaluated in the context of 
CT-P13 IV induction treatment. This treatment strategy is 
reflected in the current EU prescribing information, as CT- 
P13 SC treatment should be initiated as maintenance therapy 
following induction with CT-P13 IV.4 For ustekinumab, a pilot 
study recently evaluated induction therapy with the SC (rather 
than IV) formulation in patients with CD, establishing com-
parability of PK and acceptability of the approach.136
Supporting the uptake of innovative biologics through 
patient empowerment: dissemination of evidence and 
education
Dissemination of evidence and education is important to sup-
port the uptake of therapeutics developed through innovative 
approaches, with accumulating evidence positively influencing 
patient, HCP, and payer perceptions (Supplementary Figure 8). 
For biosimilars, patient understanding of the rationale for their 
development has been crucial to support successful biologic 
treatment initiation with, or switching to, biosimilars. 
Concerns surrounding the safety and efficacy of biosimilars 
had to be addressed,137 with real-world data helping to 
improve physician confidence toward biosimilar use in indica-
tions approved by extrapolation, such as IBD.138–140 In addi-
tion, nocebo effects resulting from negative patient perceptions 
have been observed in studies of patients with IMIDs switching 
from RPs to biosimilars.141 Such nocebo effects pose a risk to 
biosimilar uptake, treatment adherence and potential cost 
savings.141 However, strategies for minimizing the risk of 
patients with IMIDs experiencing nocebo effects have been 
widely discussed, including providing tailored educational 
initiatives for patients and HCPs (to address knowledge gaps 
and misconceptions).139,142 Medical society position papers 
and recommendations can also deliver valuable guidance and 
advocacy for the use of biosimilars.138,139 Furthermore, the 
importance of patient–HCP relationships in avoiding nocebo 
effects has been noted in the context of IMIDs, with positive 
framing, open communication, and shared decision-making 
often beneficial.137,139,142 Nurses may play a particularly 
important role in addressing concerns for patients with IBD, 
for example, due to their frequent interaction with 
patients.137,139,140 Similar educational approaches, targeting 
both patients and HCPs, may be important to support the 
introduction of VAMs and biobetters, as the concepts become 
established. For biosimilars, differences in regulatory require-
ments between countries were highlighted as a barrier to 
acceptance by healthcare systems, HCPs, and patients, and 
regulatory alignment is recommended.143 This too might be 
an important consideration for biobetters and VAMs.
Benefits and challenges of innovative biologics: the 
developers’ perspective
Developers must be cost competitive throughout the process of 
research, development, manufacturing, and distribution of 
innovative biologics, while maintaining product quality, sus-
tainable supply, and proper pharmacovigilance systems. 
Balancing this investment, pricing and market access policies 
that support long-term market sustainability and healthy com-
petition should be encouraged, as discussed for biosimilars.144 
In the context of multiple competitors, additional innovation 
could enable a product to be competitive in the biologics 
market: this in turn might determine the future success of 
a biologic developer.
Targeting unmet clinical needs is fundamental to successful 
development of biobetters and VAMs120,145,146 – a factor 
shown to support price premiums in an analysis of repurposed 
drugs.147 Consultation with patient groups and HCPs may help 
to ensure that development appropriately addresses such 
needs.120 Once an unmet need has been identified, the size of 
the potential market must be quantified to ensure the viability 
of product development.146
Drug repositioning or reformulation could offer cost- 
effective and reduced-risk routes for drug development.37 
Repositioned drugs may be eligible for patent protection, if 
sufficient evidence is available and the novelty and inventive-
ness of the new use can be demonstrated,148 while composition 
of matter patent protection may be available for medicines 
incorporating new formulations, delivery mechanisms, or 
combinations of active pharmaceutical ingredients.149 
Biobetters that offer advantages over RPs and any biosimilars 
may be patentable, and will benefit from data and market 
exclusivity rights.30 Once licensed, medicines with FDA 
approval under the 505(b)(2) pathway could benefit from 3- 
or 5-year exclusivity (depending on new clinical data or che-
mical entities),74 while per the EMA, an additional year of data 
exclusivity and/or market protection might be granted for 
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repositioned drugs (although for market protection, only if the 
new indication is registered within 8 years of initial 
approval).148 In contrast, the EMA incorporates any changes 
in strength, pharmaceutical form, and route of administration 
under the “global marketing authorization” concept, meaning 
that data and marketing protections are determined solely by 
the initial authorization.150 Regardless of patent protection for 
the new medicine, patents for the RP should not delay product 
launches for biobetters (unlike the situation for biosimilars), 
while increased differentiation from the RP could reduce the 
risk of patent litigation.30
In terms of pricing, biosimilars have been offered at discounts of 
up to 90% compared with RP list prices,9 while biosimilar competi-
tion has exacerbated price erosion for RPs and biosimilars.9,151,152 
However, differentiation from RPs may allow biobetters to com-
mand higher prices153 and be less susceptible to price erosion than 
biosimilars, subject to the assessment of added value by payers. In 
addition, biobetters offering significant advantages over the RP 
could also impact the market share for biosimilars.12 In this way, 
companies with biologic–biosimilar pipelines may use biobetter 
development as a defense strategy.78 For CT-P13 SC, the SC admin-
istration route provides differentiation from all IV-administered 
anti-TNFs, which could result in its market impact extending 
beyond reference and biosimilar infliximab.
For biobetters, therapeutic advantages could potentially allow 
increased cost-effectiveness versus RPs or biosimilars, if these are 
not outweighed by increased prices. When determining pricing 
strategies, developers should consider the price range of existing 
products with the same mechanism of action, while considering 
the clinical profile and additional value of the innovative product, 
as should payers (discussed below). However, undisclosed dis-
counts for competitor products, associated with tendering, might 
present a barrier to such evaluation. Meta-analysis, meta- 
regression, and budget impact analyses could be used to help set 
the price range for innovative products. Importantly, developers 
should consider how manufacturing and formulation choices 
affect drug administration costs, as this impacts cost- 
effectiveness.154
Developers must also be mindful of the requirements and 
challenges presented by health technology assessment (HTA) 
procedures. Pricing and reimbursement issues have been iden-
tified as key hurdles to the development of VAMs120 and 
explored in a white paper.155 A significant challenge is ensuring 
that the benefits of VAMs are recognized in HTAs, and that the 
level of evidence required is aligned with the level of reward 
from HTA bodies and payers.120 This issue is particularly 
relevant for VAMs benefiting patient-reported outcomes or 
patient preferences, in part due to HTA reliance on data from 
randomized controlled trials (vs. real-world data) and impact 
on quality-adjusted life-years, which often poorly capture these 
effects.120,155 Differences in HTA approach between countries 
adds complexity, and some perspectives used can miss benefits 
for society or healthcare systems as a whole.120,155 Pricing 
policies presenting challenges for developers also include posi-
tioning based on active substance alone, or a lack of flexibility 
in pricing over time (as additional evidence emerges) or 
between indications.38,120 For drug repositioning, a lack of 
pricing incentives for innovation surrounding established 
products means that developers are substantially more likely 
to pursue drug repositioning early or at a mid-stage in the 
product life cycle, rather than after RP patent expiration.69,148
The poorly defined regulatory landscape for biobetters and 
biologic VAMs, discussed previously, also poses challenges and 
risks for developers. Compared with abbreviated biosimilar 
approval pathways, development can be more time- 
consuming and costly. However, drug repositioning could 
substantially reduce clinical development time and the risk of 
drug failure due to safety issues.148 Another important con-
sideration is that biobetters may not show clinical improve-
ments versus the RP in all indications; linked to this is the lack 
of indication extrapolation possible for biobetters, while this is 
a possibility for biosimilars.30 This uncertainty should be con-
sidered during development of any biobetter candidate, as 
differences in benefit between indications could impact the 
potential market for the biobetter.
Developers have a key role in supporting stakeholders to 
promote confidence in the uptake of innovative biologics. 
Proper management of supply chains to avoid product 
shortages will be crucial to build trust in these medicines, 
with the importance of reliable supply chains previously dis-
cussed for biosimilars.156 Pharmaceutical companies must con-
struct clinical databases to capture outcomes and long-term 
drug performance beyond the information required for regu-
latory approval, as discussed for biosimilars,157 and in line with 
pharmacovigilance requirements that regulatory authorities 
may have.40,45 In the biosimilar arena, evidence has been accu-
mulating from real-world studies,49,158 clinical study extension 
phases,158 and recently, a Phase III non-inferiority study in 
patients with CD.159 The extension phases of the PLANETRA 
and PLANETAS studies reported efficacy analyses in different 
patient subgroups and analysis populations, and implemented 
alternative statistical techniques for handling missing 
data.160,161 Taken together, this evidence may have helped to 
alleviate concerns about indication extrapolation and switch-
ing from the RP in the case of CT-P13 treatment of IBD.158,162 
Indeed, members of the European Crohn’s and Colitis 
Organisation had significantly greater confidence in biosimi-
lars in 2015 than 2013, 2 years after CT-P13 became available 
in the EU.162 Shifts in the positions of medical societies have 
also reflected the changing evidence base.140,163 To facilitate 
effective communication with relevant stakeholders, develo-
pers should consider strategies such as translation into local 
languages or providing lay summaries of data.139
Conclusions
The introduction of biologic therapies led to a paradigm shift 
in the treatment of many IMIDs, with the subsequent avail-
ability of biosimilars facilitating reductions in treatment costs 
without compromising efficacy or safety. Ensuing cost savings 
provide opportunities to treat additional patients, to expand 
eligibility criteria (such as to patients earlier in the disease 
course), or to reinvest in the healthcare system (which could 
provide additional services for patients or increase capacity). 
Regulators formulated dedicated biosimilar review pathways, 
expediting their assessment, approval and availability for 
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patients. In light of advancing technologies and innovative 
approaches, biologics with differences from the RP – offering 
improvements for patients, including in terms of conveni-
ence and acceptability – are being produced, which could 
allow developers to be competitive in a crowded biosimilars 
market. However, these innovative biologics face obstacles, 
particularly related to nomenclature, regulatory pathways, 
and pharmacoeconomic assessment. Terms such as “VAM” 
and “biobetter” have been used to describe such products, 
although a lack of consensus on their definitions might cause 
confusion regarding the differences and potential benefits 
that an innovative biologic may offer versus the original 
biologic. A lack of clear guidance and alignment between 
regulatory agencies in terms of requirements for the 
approval of VAMs or biobetters poses further challenges 
for developers and could hinder HCP and patient confidence 
in these medicines. As for biosimilars, pharmacoeconomic 
evaluations may need to be revisited and approaches tailored 
to ensure that the benefits of VAMs or biobetters for 
patients are recognized. Timely regulatory and healthcare 
policy decisions would expedite achieving the benefits of 
innovative medicines, including cost savings for healthcare 
systems, to their full potential. Thus, there is a pressing need 
to streamline and align regulatory decision-making processes 
across different regions. Ultimately, collaboration between 
healthcare systems, HCPs, and manufacturers is key to 
improving patient access to innovative medicines 
(Supplementary Figure 9). Long-term efficacy, safety, and 
immunogenicity data, including evaluation of drug retention 
rates, will be required to support the uptake of VAMs and 
biobetters, as for biosimilars.
In the case of CT-P13, an SC formulation has been devel-
oped, offering a change in administration route versus CT-P13 
IV and the infliximab RP. Clinical studies have demonstrated 
that CT-P13 SC offers benefits in terms of PK profile compared 
with CT-P13 IV, with higher and more stable trough serum 
concentrations maintained, alongside comparable efficacy and 
overall safety profiles. Despite the perceived increased immu-
nogenicity of the SC administration route, the dosing schedule 
evaluated to date for CT-P13 SC has elicited similar immuno-
genicity as CT-P13 IV treatment; high-zone tolerance provides 
one potential explanation for these observations. Experience 
with CT-P13 SC evaluation by the EMA and FDA has high-
lighted differences in their approaches to assessing this type of 
innovative biologic. The FDA has perceived CT-P13 SC as 
a new drug, requiring pivotal clinical trials in each indication, 
while the EMA required a “hybrid” dataset including clinical 
studies additional to those needed for the biosimilar approval 
pathway.
The novel formulation and change in administration 
route of CT-P13 SC may provide potential benefits for 
patients in terms of PK profile and convenience versus CT- 
P13 IV. Given the lack of consensus surrounding the 
nomenclature for innovative biologics, these features mean 
that it could be appropriate to describe CT-P13 SC as either 
a biologic VAM or a biobetter. Ultimately, regardless of the 
terminology used, innovative biologics like CT-P13 SC 
should be able to deliver additional benefits for patients 
compared with RPs, within the resource constraints of health 
care systems.
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AUC area under the concentration–time curve
BLA Biologics License Application
CD Crohn’s disease
CI confidence interval
CLL chronic lymphocytic leukemia
Cmax maximum serum concentration
CRP C-reactive protein
Ctrough trough serum concentration
DAS28 Disease Activity Score in 28 joints
DDW Digestive Disease Week®
ECCO European Crohn’s and Colitis Organisation
ECL electrochemiluminescent
ELISA enzyme-linked immunosorbent assay
EMA European Medicines Agency
EU European Union
EULAR European League Against Rheumatism
FDA Food and Drug Administration
HCP healthcare professional
HTA health technology assessment
IBD inflammatory bowel disease
IM intramuscular





Q2W every 2 weeks





TNF tumor necrosis factor
UC ulcerative colitis
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